戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 adalafil is a novel long-acting inhibitor of phosphodiesterase-5.
2                                              Phosphodiesterase 5 activity was measured in lung, vascu
3 S-LTP identified vardenafil and Bay-73-6691 (phosphodiesterase-5 and -9 inhibitors, respectively) as
4            nNOS(S1412A) ileum expressed less phosphodiesterase-5 and was more sensitive to relaxation
5 d cGMP, but the isolated first GAF domain of phosphodiesterase 5 binds with K:(d) = 650 nM.
6 ibition of Ca(2+) channel, BK(Ca) channel or phosphodiesterase-5 did not.
7 ism, angiogenesis, adrenergic signaling, and phosphodiesterase-5 expression.
8 tochemical assay confirmed the expression of phosphodiesterase-5 in mouse cardiomyocytes.
9 te mitochondria and that sildenafil-mediated phosphodiesterase 5 inhibition ameliorates dystrophic pa
10                                              Phosphodiesterase 5 inhibition with sildenafil improves
11  protein phosphatase 2 A abundance following phosphodiesterase 5 inhibition.
12           In the double-blind PASSION study (Phosphodiesterase-5 Inhibition in Patients With Heart Fa
13                                      Because phosphodiesterase-5 inhibition leads to improved lung hi
14  of signaling downstream of endogenous NO by phosphodiesterase-5 inhibition protects against high fat
15 h preserved ejection fraction (HFpEF) in the PhosphodiesteRasE-5 Inhibition to Improve Clinical Statu
16  preserved ejection fraction enrolled in the PhosphodiesteRasE-5 Inhibition to Improve CLinical Statu
17                                       RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Statu
18                                   The RELAX (Phosphodiesterase-5 Inhibition to Improve Clinical Statu
19                   Among patients with HFPEF, phosphodiesterase-5 inhibition with administration of si
20                                              Phosphodiesterase-5 inhibition with sildenafil compared
21 , therapeutic interventions, such as in vivo phosphodiesterase 5-inhibition, which effectively abroga
22                     Here, we report that the phosphodiesterase 5 inhibitor (PDE5) sildenafil (Viagra)
23     Endothelin receptor antagonist (ERA) and phosphodiesterase 5 inhibitor (PDE5i) combination therap
24                                              Phosphodiesterase 5 inhibitor (PDE5i) treatment is assoc
25                         The combination of a phosphodiesterase 5 inhibitor and inhaled NO may have cl
26 rdiovascular function, a clinical trial of a phosphodiesterase 5 inhibitor increased rates of admissi
27 ric oxide donor sodium nitroprusside and the phosphodiesterase 5 inhibitor sildenafil compared with h
28    This study investigated the effect of the phosphodiesterase 5 inhibitor sildenafil on the pulmonar
29                  Sildenafil, an FDA-approved phosphodiesterase 5 inhibitor that enhances NO signaling
30               We tested whether tadalafil, a phosphodiesterase 5 inhibitor used to treat erectile dys
31 ho was receiving treatment with tadalafil, a phosphodiesterase 5 inhibitor, developed bilateral, conc
32                 We found that, sildenafil, a phosphodiesterase 5 inhibitor, induced mitochondrial bio
33      We studied the effects of sildenafil, a phosphodiesterase 5 inhibitor, on coronary and periphera
34                Treating S63del mice with the phosphodiesterase 5 inhibitor, sildenafil-to raise cGMP-
35                               Furthermore, a phosphodiesterase 5 inhibitor, vardenafil, synergizes wi
36                                              Phosphodiesterase-5 inhibitor (PDE5i) treatment for erec
37 SC using an arginase-1 inhibitor (CB1158) or phosphodiesterase-5 inhibitor (tadalafil) during radiati
38  was similar to that in PHIRST, with typical phosphodiesterase-5 inhibitor adverse events.
39                         Tadalafil is an oral phosphodiesterase-5 inhibitor approved for PAH treatment
40 bination of endothelin receptor antagonist + phosphodiesterase-5 inhibitor drugs and clinical evaluat
41 candidates for treatment with either an oral phosphodiesterase-5 inhibitor or an oral endothelin-rece
42 onically inhibiting cGMP hydrolysis with the phosphodiesterase-5 inhibitor sildenafil improves energy
43  this study was to assess the effects of the phosphodiesterase-5 inhibitor sildenafil, on I/R injury
44 ts with SCD, administration of sildenafil, a phosphodiesterase-5 inhibitor that potentiates NO-depend
45  therapy and a strong recommendation against phosphodiesterase-5 inhibitor therapy.
46      Previous studies have shown benefits of phosphodiesterase-5 inhibitor treatment for erectile dys
47 designed to evaluate effects of tadalafil, a phosphodiesterase-5 inhibitor used for the treatment of
48                   Treatment of mice with the phosphodiesterase-5 inhibitor vardenafil (Levitra) mobil
49                        Whether sildenafil, a phosphodiesterase-5 inhibitor, improves cerebrovascular
50                                Sildenafil, a phosphodiesterase-5 inhibitor, induces cardioprotection
51 e signaling pathway, we assessed whether the phosphodiesterase-5 inhibitor, sildenafil (SIL), could a
52                    Activation of VASP by the phosphodiesterase-5 inhibitor, sildenafil, in db/db mice
53                                          The phosphodiesterase-5 inhibitor, sildenafil, potentiates N
54    Endothelin receptor antagonists (ERA) and phosphodiesterase 5 inhibitors (PDE5I) are long-term the
55 uctase inhibitors (such as finasteride), and phosphodiesterase 5 inhibitors (such as tadalafil) impro
56 itial combination therapy (for example, with phosphodiesterase 5 inhibitors and endothelin receptor a
57                       The existence of three phosphodiesterase 5 inhibitors has resulted in an increa
58      We speculate that beneficial effects of phosphodiesterase 5 inhibitors in the systemic vasculatu
59                                   The use of phosphodiesterase 5 inhibitors is an additional risk fac
60   Early studies showed beneficial effects of phosphodiesterase 5 inhibitors on cardiovascular functio
61 annel blockers (especially nifedipine), then phosphodiesterase 5 inhibitors or intravenous iloprost.
62                             Monotherapy with phosphodiesterase 5 inhibitors seems to be as effective
63 mation by statins, pulmonary hypertension by phosphodiesterase 5 inhibitors, muscle weakness by exerc
64 acterized the off-target drug binding of two phosphodiesterase 5 inhibitors, vardenafil and sildenafi
65 ith SCD, possibly precipitated by the use of phosphodiesterase 5 inhibitors.
66                                              Phosphodiesterase-5 inhibitors (PDE-5i, such as Sildenaf
67                                       Use of phosphodiesterase-5 inhibitors (PDE5i) for groups 2 and
68       Selective pulmonary vasodilators, like phosphodiesterase-5 inhibitors (PDE5i), are used off-lab
69                                              Phosphodiesterase-5 inhibitors (PDE5Is) improve erectile
70  received PH-targeted therapy, predominantly phosphodiesterase-5 inhibitors (PDE5is).
71 ered by cinaciguat, riociguat, and different phosphodiesterase-5 inhibitors and beneficial actions of
72                                              Phosphodiesterase-5 inhibitors and other cyclic guanosin
73                                              Phosphodiesterase-5 inhibitors are a promising method to
74                                              Phosphodiesterase-5 inhibitors enhanced proteasomal degr
75  promising recent research in treatment with phosphodiesterase-5 inhibitors in single ventricle patie
76 imental and human heart failure suggest that phosphodiesterase-5 inhibitors may enhance cardiovascula
77                                              Phosphodiesterase-5 inhibitors prevent the breakdown of
78                                              Phosphodiesterase-5 inhibitors restore NO signaling and
79 rate that the increase of cGMP levels by the phosphodiesterase-5 inhibitors sildenafil and vardenafil
80 erosclerotic ED and a suboptimal response to phosphodiesterase-5 inhibitors were enrolled in this pro
81                                       PDE5i (phosphodiesterase-5 inhibitors) are used to treat pulmon
82 lin and its analogs, endothelin antagonists, phosphodiesterase-5 inhibitors, and now a soluble guanyl
83 f ABCG2, such as tyrosine kinase inhibitors, phosphodiesterase-5 inhibitors, and the fumitremorgin-ty
84 ed nitric oxide, sodium nitrite, L-arginine, phosphodiesterase-5 inhibitors, niacin, inhaled carbon m
85 ith prostanoids, endothelin-1 inhibitors and phosphodiesterase-5 inhibitors, or a combination of ther
86 ailable-ie, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, soluble guanylate cyclas
87 MP/PKG2 signaling, and can be targeted using phosphodiesterase-5 inhibitors.
88 ysfunction (ED) and a suboptimal response to phosphodiesterase-5 inhibitors.
89                      These results show that phosphodiesterase-5 is a potential target for therapies
90 ight benefit cardiovascular diseases because phosphodiesterase-5 is also located elsewhere in the bod
91 ivation and inhibition of the cGMP-degrading phosphodiesterase-5, ischemic preconditioning, and postc
92 ilable for immunohistochemical assessment of phosphodiesterase-5 isoenzyme (PDE-5) and PDE-2 expressi
93 eating various cell lines with inhibitors of phosphodiesterase 5 or stimulators of soluble guanylyl c
94            Sildenafil, a potent inhibitor of phosphodiesterase-5 (PDE-5) induces powerful protection
95                We have shown that the potent phosphodiesterase-5 (PDE-5) inhibitor sildenafil (Viagra
96                                              Phosphodiesterase-5 (PDE-5) inhibitors and endothelin-1
97      Current pharmacologic therapies include phosphodiesterase-5 (PDE-5) inhibitors, such as sildenaf
98                  Inhibition of cGMP-specific phosphodiesterase 5 (PDE5) ameliorates pathological card
99  nitric oxide by restraining the activity of phosphodiesterase 5 (PDE5) by acting as a substrate adap
100                      The molecular bases for phosphodiesterase 5 (PDE5) catalytic-site affinity for c
101                                              Phosphodiesterase 5 (PDE5) controls intracellular levels
102                                              Phosphodiesterase 5 (PDE5) hydrolyzes cyclic guanosine m
103                                Inhibition of phosphodiesterase 5 (PDE5) improves cardiac function in
104 e aim of this work was to test whether acute phosphodiesterase 5 (PDE5) inhibition via sildenafil (SI
105 dystrophin, restoration of nNOS effects by a phosphodiesterase 5 (PDE5) inhibitor (sildenafil) improv
106        Preclinical studies indicate that the phosphodiesterase 5 (PDE5) inhibitor sildenafil is prote
107                            Surprisingly, the phosphodiesterase 5 (PDE5) inhibitor sildenafil was foun
108 rse of nitrate interaction with tadalafil, a phosphodiesterase 5 (PDE5) inhibitor with a half-life (t
109 gated whether sildenafil citrate (Viagra), a phosphodiesterase 5 (PDE5) inhibitor, can be used to ame
110                    Addition of sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, in the drinking wa
111 iptional modulation by sildenafil, a popular phosphodiesterase 5 (PDE5) inhibitor.
112 udies determined whether clinically relevant phosphodiesterase 5 (PDE5) inhibitors interacted with cl
113                                              Phosphodiesterase 5 (PDE5) inhibitors limit myocardial i
114             Observational studies found that phosphodiesterase 5 (PDE5) inhibitors use is linked to b
115 tivation and CXCL13 induction are blocked by phosphodiesterase 5 (PDE5) inhibitors.
116  by the chronic inhibition of cGMP-selective phosphodiesterase 5 (PDE5) suppressed maladaptive cardia
117                     Substrate binding to the phosphodiesterase-5 (PDE5) catalytic site increases cGMP
118                                              Phosphodiesterase-5 (PDE5) contains a catalytic domain (
119                          Here we report that phosphodiesterase-5 (PDE5) gene expression and PDE activ
120      Recently, targeting cyclic-GMP specific phosphodiesterase-5 (PDE5) has attracted much interest i
121 oth muscle cells (PASMCs), and inhibition of phosphodiesterase-5 (PDE5) has been shown to suppress TR
122                                Sildenafil, a phosphodiesterase-5 (PDE5) inhibitor causing accumulatio
123 of vardenafil, a potent and highly selective phosphodiesterase-5 (PDE5) inhibitor, on symptom-limited
124                                              Phosphodiesterase-5 (PDE5) inhibitors (sildenafil, tadal
125                                              Phosphodiesterase-5 (PDE5) inhibitors and other agents t
126                                              Phosphodiesterase-5 (PDE5) inhibitors are suggested to h
127                                              Phosphodiesterase-5 (PDE5) inhibitors improve exercise c
128                                              Phosphodiesterase-5 (PDE5) inhibitors increase intracell
129                                              Phosphodiesterase-5 (PDE5) inhibitors promote nitric oxi
130                              The activity of phosphodiesterase-5 (PDE5) is specific for cGMP and is r
131                                              Phosphodiesterase-5 (PDE5) is the target for sildenafil,
132            Vardenafil has higher affinity to phosphodiesterase-5 (PDE5) than sildenafil and lower adm
133 peting with this nucleotide for catalysis by phosphodiesterase-5 (PDE5), but the characteristics of d
134 ach competitively inhibit cGMP hydrolysis by phosphodiesterase-5 (PDE5), thereby fostering cGMP accum
135                          Sildenafil inhibits phosphodiesterase 5 (PDE5A) to elevate intracellular cGM
136 d by cGMP-dependent allosteric activation of phosphodiesterase 5, which shapes the amplitude and dura
137 il is a clinically relevant drug that blocks phosphodiesterase 5 with high specificity and is used to

 
Page Top